Literature DB >> 2892447

The metabolism and pharmacokinetics of 14C-cetirizine in humans.

S G Wood1, B A John, L F Chasseaud, J Yeh, M Chung.   

Abstract

This study investigated the metabolism and pharmacokinetics of cetirizine, a new H1-receptor antagonist. Single oral doses of 14C-cetirizine dihydrochloride (10 mg) in aqueous solution were administered to six healthy male volunteers. The drug was rapidly absorbed: The peak mean concentration of radioactivity (359 ng-equivalents/mL) and of unchanged drug (341 ng/mL) were achieved within one hour. Mean concentrations of cetirizine declined biexponentially and had a mean elimination half-life of 7.4 hours. The drug was excreted quite rapidly, with 60% of the dose recovered in the 24-hour urine. An additional 10% was excreted in urine over the next four days. Approximately 10% of the dose was excreted in feces over the five-day study period. The dose was excreted mainly as the unchanged drug. Examination of the radioactive compounds present in the plasma, and excreted in the urine and feces indicate that there is little metabolism of cetirizine. One minor metabolite, formed by oxidative O-dealkylation of the cetirizine side chain, was detected in plasma and feces.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2892447

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  17 in total

1.  Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h.

Authors:  A Purohit; M Mélac; G Pauli; N Frossard
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 2.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Comparison of the central and peripheral effects of cetirizine and terfenadine.

Authors:  J C Pechadre; D Vernay; J F Trolese; M Bloom; P Dupont; J P Rihoux
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 5.  Cetirizine. An updated review of its pharmacological properties and therapeutic efficacy.

Authors:  J P Rihoux; S Mariz
Journal:  Clin Rev Allergy       Date:  1993

Review 6.  Clinical pharmacology of new histamine H1 receptor antagonists.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 7.  Optimum pharmacological management of chronic rhinitis.

Authors:  F E Simons; K J Simons
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

8.  Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers.

Authors:  G Peytavin; C Gautran; C Otoul; A C Cremieux; B Moulaert; F Delatour; M Melac; M Strolin-Benedetti; R Farinotti
Journal:  Eur J Clin Pharmacol       Date:  2005-05-12       Impact factor: 2.953

9.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.